China Resources Pharmaceutical Group (HKG:3320) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥257.7b (up 5.3% from FY 2023).
- Net income: CN¥3.33b (down 14% from FY 2023).
- Profit margin: 1.3% (down from 1.6% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: CN¥0.53 (down from CN¥0.61 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
China Resources Pharmaceutical Group Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 21%.
The primary driver behind last 12 months revenue was the Distribution segment contributing a total revenue of CN¥213.2b (83% of total revenue). Notably, cost of sales worth CN¥217.0b amounted to 84% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥19.8b (53% of total expenses). Explore how 3320's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong.
Performance of the Hong Kong Pharmaceuticals industry.
The company's shares are down 1.4% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for China Resources Pharmaceutical Group that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.